Titlebook: Drug Repurposing for Emerging Infectious Diseases and Cancer; Ranbir Chander Sobti,Sunil K. Lal,Ramesh K. Goyal Book 2023 The Editor(s) (i

JEER

Why Macroprudential Policy? Brief Overviewh results in improved outcomes therapeutically. We have described the immunomodulatory mechanism associated with the cancer treatment involving the cytokines, adjuvants, checkpoints, and agonists and hypothesized restricting tumour development by interrupting the tumour cell cycle and promoting apop

Foreshadow

Kyuil Chung,Soyoung Kim,Hyun Song Shinthis field, could lead to the discovery of new anticancer drugs. Throughout this chapter, an overview of drug repositioning for anticancer applications, with a specific emphasis on activity-based drug repositioning of non-cancer medicines is provided. Several effective case studies of drug repurposi

acclimate

NATAL

Substitution

Violence and Visibility in Modern Historye imatinib, saracatinib, and homoharringtonine, which have been studied for other coronaviruses in the past. Furthermore, current anticancer drugs like carmofur, carfilzomib, zotatifin, plitidepsin, and toremifene have gained interesting outcomes with respect to SARS-CoV-2. It is well recognized tha

Melatonin

Drug Repurposing for Emerging Infectious Diseases and Cancer

mediocrity

Drug Repurposing for Emerging Infectious Diseases and Cancer978-981-19-5399-6

Arrhythmia

Drug Repurposing: An Advance Way to Traditional Drug Discovery,approaches are already developed to increase the speed and ease of the repurposing process. With the advancement of technologies such as proteomics, genomics, transcriptomics, metabolomics and the availability of massive databases resources such as drug omics data, disease omics data and so on, ther

Iatrogenic

Pharmacovigilance-Based Drug Repurposing,drugs which are already approved for any condition. Inverse signaling approach takes cues from data mining approaches, applied to pharmacovigilance databases. Currently, this approach is being tried to evaluate existing compounds for Raynaud’s phenomenon, COVID-19, Alzheimer’ disease, etc. In this c

colony

Drug Repurposing Opportunities in Cancer,t chapter, we have discussed the importance of repurposed therapeutics, barriers in DR, and computational approaches in DR..The opportunities of repurposing small-molecules non-oncology therapeutics and phytochemicals against assorted cancers are also discussed. Furthermore, repurposed cargos in cli